Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

News
Video

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer.

Related Videos
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Related Content
Ken Takeshita, MD

Dato-DXd Does Not Elicit Significant OS Improvement in Previously Treated, Advanced NSCLC

May 28th 2024
Article
Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024
Podcast
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024
Article
Lung Cancer | Image Credit: © Axel Kock - stock.adobe.com

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16th 2024
Article